Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2013, 5(1), 64-91; doi:10.3390/cancers5010064
Review

Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy

* ,
,
,
,
 and
Received: 3 December 2012; in revised form: 1 January 2013 / Accepted: 14 January 2013 / Published: 21 January 2013
(This article belongs to the Special Issue Gastric Cancer)
View Full-Text   |   Download PDF [302 KB, uploaded 21 January 2013]
Abstract: Gastric cancer (GC) represents a major cancer burden worldwide, and remains the second leading cause of cancer-related death. Due to its insidious nature, presentation is usually late and often carries a poor prognosis. Despite having improved treatment modalities over the last decade, for most patients only modest improvements have been seen in overall survival. Recent progress in understanding the molecular biology of GC and its signaling pathways, offers the hope of clinically significant promising advances for selected groups of patients. Patients with Her-2 overexpression or amplification have experienced benefit from the integration of monoclonal antibodies such as trastuzumab to the standard chemotherapy. Additionally, drugs targeting angiogenesis (bevacizumab, sorafenib, sunitinib) are under investigation and other targeted agents such as mTOR inhibitors, anti c-MET, polo-like kinase 1 inhibitors are in preclinical or early clinical development. Patient selection and the development of reliable biomarkers to accurately select patients most likely to benefit from these tailored therapies is now key. Future trials should focus on these advances to optimize the treatment for GC patients. This article will review recent progress and current status of targeted agents in GC.
Keywords: gastric cancer; molecular targeted agents; monoclonal antibody; tyrosine kinase inhibitor gastric cancer; molecular targeted agents; monoclonal antibody; tyrosine kinase inhibitor
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Cidon, E.U.; Ellis, S.G.; Inam, Y.; Adeleke, S.; Zarif, S.; Geldart, T. Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy. Cancers 2013, 5, 64-91.

AMA Style

Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T. Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy. Cancers. 2013; 5(1):64-91.

Chicago/Turabian Style

Cidon, Esther U.; Ellis, Sara G.; Inam, Yasir; Adeleke, Sola; Zarif, Sara; Geldart, Tom. 2013. "Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy." Cancers 5, no. 1: 64-91.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert